Cancer Genetics Explained: How Tumors Hijack DNA and Scientific Breakthroughs that Fight Back

Across this site we have counted what genetic medicine has actually delivered, and the picture is usually sobering. Senolytics: 31 registered trials, five completed. CRISPR: 150 trials, more abandoned than finished. Polygenic embryo screening: zero.

Cancer is the exception, and it is not close. ClinicalTrials.gov lists 20,799 studies involving targeted cancer therapy, 10,176 involving immunotherapy and 4,060 involving tumour sequencing (searched 7 October 2026). This is where reading a genome already changes what happens to a patient tomorrow.

The reason is worth understanding, because it explains both why cancer genetics succeeded and why other fields have struggled. Cancer is a disease of the genome, the mutations are present in the tissue you can biopsy, and the effect of blocking one is measurable in months rather than decades.

In December 2025, researchers at the University of California San Diego published a finding in Science that changed how scientists understand one of the most destructive events in tumour development. They identified an enzyme that starts chromothripsis — a catastrophic process in which a chromosome is shattered into dozens or hundreds of fragments, then randomly reassembled in the wrong order. The enzyme is called N4BP2.

Chromothripsis had been described in 2011, but how the shattering begins had been unclear. The largest whole-genome survey, of 2,658 tumours, found it in about 29 per cent of cancers, so understanding how it starts means understanding a process that shapes the genomes of more than a quarter of all tumours.

Cancer is not a single disease. It is a vast collection of diseases — over 100 distinct types — united by one fundamental characteristic: cells that have lost the genetic controls regulating their growth and division, and that now multiply without limit, invade surrounding tissue, and spread to distant organs. At its core, cancer is a disease of DNA. Every case begins with a genetic error — a mutation, a deletion, an amplification, a rearrangement — that disrupts the machinery keeping cell division under precise control.

In a real sense, cancer is evolution happening inside you, at cellular speed. Understanding that machinery — how it works, how it breaks, and how it can be repaired or targeted — is advancing faster in 2026 than at any previous point in history.

What Happens to DNA When Cancer Develops

Every cell in your body divides according to a tightly regulated programme. When a cell divides, it copies its entire genome — about three billion base pairs of DNA — and gives one complete copy to each daughter cell. The process is not perfectly accurate: each division leaves a few new copying errors behind. A 2017 study in Science by Cristian Tomasetti, Lu Li and Bert Vogelstein of Johns Hopkins estimated that such replication errors account for about two-thirds of the mutations found in human cancers, with inherited and environmental causes making up the rest. It is an influential estimate and a contested one, but either way chance plays a larger part than most people assume.

Most of these mutations are harmless. They fall in regions that do not affect function, or are corrected by the cell’s repair machinery before they cause damage. A small fraction, however, land in genes that regulate cell growth — and there they can tip the balance between controlled proliferation and cancer.

Researchers distinguish two broad categories of cancer-relevant genes. Oncogenes, when mutated, actively drive cell growth — like a stuck accelerator. Tumour suppressor genes normally restrain division — like a brake. Cancer typically involves both: oncogenes switched on inappropriately, and tumour suppressors inactivated. Cancer development is not random but evolutionary: mutations that give a cell a survival advantage are selected over time, building on one another across successive cell generations. A single mutation is rarely enough; most tumours require several genetic alterations, accumulated over years or decades, before a cell turns fully malignant.

The Hallmarks of Cancer, Updated for 2026

In 2000, Douglas Hanahan and Robert Weinberg published one of the most influential papers in the history of cancer biology, describing the “hallmarks of cancer” — a set of acquired capabilities that separate cancer cells from normal ones. The original list held six. In 2011 the two added abnormal metabolism and evasion of the immune system, plus two “enabling” traits, genome instability and inflammation. In 2022 Hanahan proposed further additions, and in January 2026 he published a 25-year synthesis in Cell arguing that attacking several hallmarks at once, guided by their mechanisms, could be one of the most promising new treatment strategies.

These include sustained growth signalling, in which cancer cells generate their own growth signals; resistance to the mechanisms that would normally suppress excessive growth; evasion of programmed cell death; and replicative immortality — achieved largely by reactivating telomerase, the enzyme that maintains telomere length, as explored in our article on telomeres and ageing. Cancer cells also stimulate the growth of new blood vessels to feed the tumour, and invade surrounding tissue to spread through the bloodstream to distant organs — the metastasis that makes cancer so lethal.

The 2022 additions were phenotypic plasticity, the ability of cancer cells to switch between different states, which makes them harder to target; epigenetic reprogramming, silencing tumour suppressor genes through chemical marks rather than mutation; the influence of the microbes living in and around tumours; and senescent cells, which can fuel tumours from the surrounding tissue.

Oncogenes: The Molecular Accelerators

Among the most studied oncogenes are the RAS family — KRAS, HRAS, and NRAS — which encode proteins that act as molecular switches in cell signalling, toggling between active and inactive states to control growth. When mutated, the switch jams permanently in the “on” position, driving division regardless of external signals.

KRAS mutations are among the most common cancer drivers across many tumour types, including colorectal, lung, and pancreatic cancers. For decades KRAS was considered “undruggable” — its structure offered no obvious pocket for a drug to grip. The first inhibitor of one variant, KRAS G12C, was approved in the United States for lung cancer in May 2021, but G12C is only one of many KRAS mutations and is rare in pancreatic cancer, and resistance emerges in most treated patients. The newer approach blocks many RAS variants at once, as the pancreatic results below show. HER2 is another oncogene of major clinical importance: gene amplification, in which a stretch of DNA is duplicated many times, can cause HER2 to be massively overexpressed, driving aggressive growth. HER2-targeted therapies have transformed treatment of HER2-positive breast cancer, and testing for HER2 amplification is now routine.

Pancreatic Cancer, GATA6 and the First RAS Drug

Pancreatic cancer is one of the deadliest cancers. In the United States only about 13 per cent of patients are alive five years after diagnosis, a figure the American Cancer Society reported in 2026 as essentially unchanged, largely because the disease is usually detected late and rapidly develops resistance to chemotherapy. Caught while still confined to the pancreas, 44 per cent of patients survive five years; once it has spread to distant organs, just 3 per cent do. More than 90 per cent of these tumours carry a mutated RAS gene.

A gene called GATA6 helps decide how those tumours behave. High GATA6 marks the “classical” form of pancreatic cancer, which is more differentiated, closer to normal pancreatic tissue, and has a better outlook. Low GATA6 marks the “basal-like” form, more primitive and harder to treat. A study from Duke-NUS Medical School in Singapore, published in the Journal of Clinical Investigation in early 2026, found what switches GATA6 off: the mutant KRAS signal itself, acting through a protein called JUNB.

In laboratory experiments, blocking the KRAS signal let GATA6 return, made pancreatic cancer cells more sensitive to chemotherapy, and worked together with chemotherapy in a GATA6-dependent way. That suggests a strategy beyond attacking cancer cells directly: push resistant tumours back into a treatable state, then treat them. It has not yet been tested in patients, but the drugs to test it now exist.

The biggest of them arrived in 2026. Daraxonrasib, a pill that blocks the active form of many RAS variants at once, was compared with chemotherapy in 500 patients whose metastatic pancreatic cancer had progressed after earlier treatment. Median survival was 13.2 months with daraxonrasib against 6.7 months with chemotherapy, and serious side effects were no more common; only 1.2 per cent stopped the drug because of them, against 11.2 per cent on chemotherapy. The results appeared in the New England Journal of Medicine, and on 26 August 2026 the FDA approved the drug, with warnings about skin reactions, mouth sores, diarrhoea, bowel perforation and lung inflammation. A median of just over a year is still short, but in this disease it is the largest gain in decades.

A Hidden Layer of Cancer: RNA and Epigenetics

In February 2026, a team at the University of California San Francisco described a class of small RNA molecules that appear in cancer cells but not in the normal tissue around them. They call them orphan non-coding RNAs. Across 32 tumour types, the pattern of which ones are present formed a kind of barcode that identified the cancer type and even its subtype, a layer of information invisible to standard DNA sequencing.

The discovery matters because cancer cells release some of these RNAs into the blood. In a look back at 192 breast cancer patients, changes in the amount circulating predicted how the patients fared, both in the short and long term. Some appear to drive tumour growth, too: switching them off slowed tumours in mice. Several of the authors work for a company developing the approach as a blood test, and the patient study was retrospective, so it needs testing forward in time before it can guide care.

Cancer’s relationship with epigenetics is equally central, as explored in our article on epigenetics and gene expression. Cancers often carry multiple epigenetic errors that reinforce one another — keeping tumour suppressor genes permanently silenced while pro-cancer genes stay active. Crucially, unlike DNA mutations these errors are potentially reversible, and several epigenetic drugs have already received regulatory approval for specific cancers.

Chromothripsis: When Chromosomes Shatter

The identification of N4BP2 is one of the most mechanistically important cancer discoveries of recent years. Chromothripsis — from the Greek for “chromosome shattering” — is a process in which a chromosome undergoes catastrophic fragmentation, producing dozens or hundreds of pieces that are then randomly stitched back together in the wrong order.

It often begins with a mistake in cell division that leaves a chromosome stranded in a micronucleus, a small, fragile pouch outside the main nucleus. The UC San Diego team, working with colleagues at the University of Cambridge and the Wellcome Sanger Institute, tested all 204 known and suspected human enzymes that cut DNA and found that N4BP2 slips into these pouches when they rupture and starts breaking the chromosome. The same enzyme helped produce circular fragments of DNA outside the chromosomes, which tumours use to carry extra copies of cancer genes, and it promoted tumour growth in a model of aggressive brain cancer. Across more than 10,000 human cancer genomes, high levels of N4BP2 predicted chromothripsis.

The rearrangements this produces can simultaneously inactivate multiple tumour suppressor genes and amplify multiple oncogenes in a single catastrophic event — compressing into one cell division what would otherwise take years of gradual mutation. In the 2020 whole-genome survey it was present in every liposarcoma examined, 77 per cent of osteosarcomas, and more than half of melanomas, glioblastomas and lung adenocarcinomas. Knowing that N4BP2 starts it opens a path toward blocking it, though no drug against the enzyme yet exists.

Precision Oncology: Treating the Mutation, Not the Organ

The most consequential shift in cancer treatment over two decades has been the move from organ-based treatment — chemotherapy designed for “breast cancer” or “lung cancer” — toward mutation-based treatment aimed at any cancer carrying a specific driver mutation, wherever it originated.

The clearest sign of that shift is the “tissue-agnostic” approval, in which a drug is licensed for a genetic feature regardless of where the tumour began. The first came in 2017, for the immunotherapy pembrolizumab in tumours with a particular DNA-repair defect. By June 2020 the FDA had made four such approvals based on a biomarker rather than the organ of origin.

In the American Association for Cancer Research’s 2026 forecast, Keith Flaherty of the Mass General Cancer Center described the year as one where novel chemistry meets earlier care, guided by precision models that move beyond DNA-only thinking. A particularly promising class is the “chemical inducers of proximity” — molecules that change what proteins do by bringing two of them together, for example forcing a cancer-promoting protein into contact with the cell’s own degradation machinery.

As explored in our article on gene editing in 2026, CRISPR-based approaches are increasingly applied to cancer — both as research tools for finding which genes cancer cells depend on, and as potential therapies targeting cancer-specific mutations with a precision conventional drugs cannot match. CAR-T cell therapy, which engineers immune cells to recognise and destroy cancer, has already produced remarkable results in blood cancers and is being pushed toward solid tumours.

Personalisation is advancing further through comprehensive tumour profiling — sequencing hundreds of cancer genes at once to identify a tumour’s mutations and the drugs most likely to work. This lets clinicians separate driver mutations, which actively promote growth, from genetically neutral passenger mutations. One number it produces, tumour mutational burden, simply counts the mutations. In June 2020 the FDA approved pembrolizumab for any advanced solid tumour with at least 10 mutations per million DNA letters, after 29 per cent of such patients in a trial responded.

Why Cancer Genetics Delivered When Others Did Not

Genetic medicine has promised a great deal and delivered unevenly. Counting registered studies on 7 October 2026 makes the unevenness stark, and cancer sits at one extreme.

• Targeted cancer therapy: 20,799 registered studies.
• Immunotherapy: 10,176.
• Tumour sequencing: 4,060.
• Precision oncology: 1,734.
• CRISPR, all applications: 150.
• Senolytics: 31.

Four features of cancer explain the gap, and none of them apply cleanly to ageing, embryo selection or most inherited disease.

The mutation is the disease. In most conditions, genetics loads the dice and environment rolls them. In cancer the driver mutations described above are the mechanism itself. Block the protein a driver mutation produces and you are not adjusting a risk factor, you are interrupting the thing that is killing the patient.

The tissue is available. A tumour can be biopsied and sequenced directly. Contrast that with a senescent cell buried in an ageing organ, or an embryo whose relevant outcome will not appear for forty years.

The endpoint arrives quickly. Tumour shrinkage and progression-free survival are measurable within months. A trial of an anti-ageing intervention may need decades before anything can be scored, which is why so few of them ever finish.

The risk calculus permits aggression. Drugs with severe side effects are acceptable in a lethal disease and unacceptable in a healthy person — the same asymmetry that has kept epigenetic drugs confined to oncology.

The honest qualifier is that trial volume measures effort, not cure. Twenty thousand studies reflect enormous investment and a great many failures alongside the successes, and targeted therapies frequently work brilliantly until resistance emerges. But the direction is real: cancer is the one area where sequencing a genome routinely changes the prescription, and it is the closest thing genetic medicine has to a finished argument.

Turning the Immune System Against Cancer

Your immune system already patrols for abnormal cells and destroys many would-be cancers before they take hold. The problem is that successful tumours evolve ways to hide. One of their favourite tricks is to exploit the immune system’s own safety brakes — molecular “checkpoints” such as PD-1, PD-L1, and CTLA-4 that normally stop immune cells attacking healthy tissue. By switching these brakes on, a tumour can render itself effectively invisible.

Checkpoint-inhibitor drugs release those brakes, unleashing the patient’s own immune cells on the cancer. The discovery of this approach earned James Allison and Tasuku Honjo the 2018 Nobel Prize in Physiology or Medicine, and it has produced durable remissions in cancers, such as advanced melanoma and some lung cancers, that were once nearly untreatable. The frontier now is understanding why only a subset of patients respond — a question that turns out to depend heavily on a tumour’s genetics, its mutational burden, and the epigenetic state of both the cancer and the immune cells around it.

Reading Cancer in a Drop of Blood

Tumours constantly shed fragments of their DNA into the bloodstream. Sequencing this circulating tumour DNA from a simple blood draw — a “liquid biopsy” — is one of the most transformative ideas in modern oncology. Instead of a painful, risky tissue biopsy, a vial of blood can reveal which mutations a tumour carries, track whether a treatment is working in near real time, and catch the emergence of drug resistance months before a scan would show it.

The most ambitious extension is multi-cancer early detection: blood tests that scan for the molecular signatures of many cancers at once, aiming to catch tumours while they are still small and curable. Because survival for most cancers depends enormously on how early they are found, a reliable test of this kind would be among the most consequential advances in the history of the disease. The science is not yet perfected — false positives and missed cancers remain real challenges — but the trajectory points toward a future in which cancer is intercepted from a routine blood sample long before symptoms appear.

The first large test of that idea reported in September 2026. The NHS-Galleri trial in England enrolled 142,250 people aged 50 to 77 and tested half of their blood each year for three years. Its main goal, fewer cancers found at stage III or IV, was not met: the rate was essentially the same in both groups. Stage IV diagnoses alone were about 14 per cent lower in the tested group, a result at the very edge of statistical significance that further follow-up must confirm. Fewer than 1 per cent of participants had a trial-related side effect, and none was serious. For now, a blood test for many cancers at once is a promise still being tested, not a proven screen.

Cancer as a Disease of Ageing

One of the most important but underappreciated aspects of cancer biology is its intimate connection to ageing. The great majority of cancers are diseases of ageing — incidence rises steeply with age, and not simply because older people have had more time to accumulate mutations.

Ageing and cancer share fundamental mechanisms. The telomere shortening that drives cellular senescence in ageing tissue also creates genomic instability: when critically short telomeres are misread as broken DNA ends and repaired incorrectly, they can fuse chromosomes together, generating the massive rearrangements that fuel malignant transformation. The build-up of senescent cells in ageing tissue creates a pro-inflammatory environment that actively promotes tumour growth and invasion.

The epigenetic changes that accumulate with age — drift in methylation patterns, gradual reorganisation of chromatin — are strikingly similar to the disruptions found in cancer cells, and may prime cells for transformation by silencing tumour suppressor genes in the same way cancer-specific events do. Cancer and ageing are not parallel processes running side by side. At the molecular level, they are deeply intertwined.

What Scientists Say

Keith Flaherty of Massachusetts General Hospital, contributing to the AACR’s 2026 expert forecast, said he was “most excited about the novel chemistry advances that will help with early interception of cancer”, pointing to molecules that bring two proteins into close proximity to change what they do, rather than simply blocking them.

The Van Andel Institute, in its outlook for cancer research in 2026, highlighted trials that combine immunotherapies with epigenetic medications “for a one-two punch against cancer”. The logic is that epigenetic silencing, unlike a DNA mutation, can in principle be reversed. Taken together, cancer genomics now lets clinicians identify the driver mutations promoting a tumour’s growth, distinguish them from harmless passenger mutations, and select targeted therapies accordingly — a shift from treating tumour type to treating tumour genotype.

The Shape of What Is Coming

Put the pieces together and a picture emerges of where cancer medicine is heading. An enzyme that starts chromothripsis has a name. The first drug to block RAS broadly has extended survival in pancreatic cancer, and the switch that links RAS to chemotherapy resistance is being mapped. Cancer-specific RNAs are being read from blood. The immune system can be unleashed against tumours, mutations can be matched to targeted drugs, and the first randomised trial of a multi-cancer blood test has shown both how hard and how important early detection is.

None of this means cancer is solved. It remains one of the most formidable adversaries in medicine precisely because it is not a fixed target but an evolving one — a Darwinian process unfolding inside the body, endlessly generating new variation for treatment to chase. But the balance of the contest is shifting. For most of history, cancer was a black box: we saw its effects and fought its symptoms without understanding its cause. Now, for the first time, we are reading the exact molecular sabotage that turns a healthy cell malignant — and learning, gene by gene, to undo it.

There is a strange intimacy to this science. Cancer is not an invader from outside; it is your own cells, your own DNA, following the logic of evolution to a destructive end. To understand cancer is, in a sense, to understand something fundamental about what it means to be a living, dividing, mutating organism. And to learn to read that story at the level of single letters of the genome is one of the quiet triumphs of our age.

Frequently Asked Questions

Sources

• Jackson Laboratory — The Hallmarks of Cancer, 2026 Edition
• Van Andel Institute — Cancer Research in 2026
• AACR — Experts Forecast Cancer Advances in 2026
• ClinicalTrials.gov — registered trial counts by approach (queried 7 October 2026)
• Hanahan — Hallmarks of Cancer: New Dimensions, Cancer Discovery 12, 31 (2022)
• Krupina et al. — Chromothripsis and ecDNA initiated by N4BP2 nuclease fragmentation of cytoplasm-exposed chromosomes, Science 390, 1156 (2025)
• Cortés-Ciriano et al. — Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing, Nature Genetics 52, 331 (2020)
• Zhong et al. — Oncogenic KRAS/ERK/JUNB signaling suppresses differentiation regulator GATA6 in pancreatic cancer, Journal of Clinical Investigation 136, e191370 (2026)
• Wang et al. — Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity, Cell Reports Medicine 7, 102577 (2026)
• O’Reilly et al. — Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer, New England Journal of Medicine 395, 325 (2026)
• FDA — FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma (26 August 2026)
• Sasieni et al. — Effect of screening with a multicancer early-detection test on late-stage cancer diagnosis, New England Journal of Medicine (2026)
• Marcus et al. — FDA approval summary: pembrolizumab for tumor mutational burden-high solid tumors, Clinical Cancer Research 27, 4685 (2021)
• Hanahan — Hallmarks of cancer: then and now, and beyond, Cell 189, 2254 (2026)
• Tomasetti, Li & Vogelstein — Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention, Science 355, 1330 (2017)
• Vogelstein et al. — Cancer genome landscapes, Science 339, 1546 (2013)
• American Cancer Society — Pancreatic cancer survival rates